Tcr2 Competitors

Delisted . USA . 
Stock . Tcr2 Therapeutics
TCRRDelisted Stock  USD 1.48  0.00  0.00%   
Tcr2 Therapeutics competes with Affimed NV, Pieris Pharmaceuticals, ADC Therapeutics, Agenus, and Revolution Medicines; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Tcr2 Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Tcr2 Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Tcr2 Therapeutics competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
1.481.481.48
Details
Intrinsic
Valuation
LowRealHigh
1.351.351.63
Details
Naive
Forecast
LowNextHigh
1.351.351.35
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.471.772.07
Details

Tcr2 Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Tcr2 Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Tcr2 and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Tcr2 Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
PASG
+ 0.84
BDTX
PASG
+ 0.81
AGEN
BDTX
+ 0.78
AFMD
PASG
+ 0.78
AFMD
BDTX
+ 0.77
AGEN
ALEC
+ 0.69
PASG
  
High negative correlations   
RVMD
- 0.82
AGEN
BDTX
- 0.79
RVMD
HARP
- 0.7
PIRS
PASG
- 0.63
RVMD
HARP
- 0.55
BDTX
RVMD
- 0.53
PIRS

Risk-Adjusted Indicators

There is a big difference between Tcr2 Stock performing well and Tcr2 Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Tcr2 Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
AFMD  2.49 (0.79) 0.00 (0.51) 0.00 
 0.00 
 6.39 
(6.82)
 21.26 
PIRS  1.56 (0.23) 0.00 (0.41) 0.00 
 0.00 
 2.69 
(3.40)
 12.92 
ADCT  3.52 (0.79) 0.00 (0.21) 0.00 
 0.00 
 6.98 
(7.81)
 22.87 
AGEN  3.56 (1.06) 0.00 (0.29) 0.00 
 0.00 
 6.43 
(8.60)
 27.05 
RVMD  2.06  0.25  0.10  0.30  2.20 
(2.13)
 4.81 
(3.90)
 10.95 
BDTX  3.84 (1.19) 0.00  19.48  0.00 
 0.00 
 5.81 
(8.30)
 26.00 
BCEL  3.90  0.23  0.02 (0.54) 5.00 
(4.64)
 7.53 
(9.65)
 23.80 
PASG  4.66 (0.57) 0.00 (0.15) 0.00 
 0.00 
 9.33 
(9.88)
 25.50 
HARP  3.55  0.43  0.11  0.44  3.28 
(5.07)
 9.59 
(6.25)
 22.48 
ALEC  4.28 (0.69) 0.00 (0.12) 0.00 
 0.00 
 8.66 
(7.89)
 26.60 
All Fundamental Data

Tcr2 Therapeutics Competitive Analysis

The better you understand Tcr2 Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Tcr2 Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Tcr2 Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
TCRR AFMD PIRS ADCT AGEN RVMD BDTX BCEL PASG HARP
 0.00 
 1.48 
Tcr2
 2.94 
 2.64 
Affimed
 0.50 
 15.93 
Pieris
 2.02 
 1.94 
ADC
 7.12 
 2.86 
Agenus
 0.53 
 57.08 
Revolution
 4.71 
 2.43 
Black
 1.89 
 1.04 
Atreca
 5.88 
 0.54 
Passage
 0.00 
 0.85 
Harpoon
Market Volatility
(90 Days Market Risk)
Very steady
Unstable
Not too volatile
Very risky
Very risky
Very steady
Very risky
Very steady
Out of control
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Good
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Very High
Very High
High
High
Low
Quite High
Dangerous
High
Dangerous
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Hold
Strong Buy
Buy
Strong Buy
Strong Buy
Not Available
Strong Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Cautious Hold
Sell
Strong Sell
Strong Sell
Hold
Strong Sell
Not Rated
Strong Sell
Not Rated
Current Ratio
5.02
4.9
2.56
5.76
1.45
7.6
8.55
8.14
9.23
1.62
Net Asset
208.24 M
97.16 M
38.68 M
354.78 M
313.91 M
2.06 B
158.57 M
155.03 M
150.54 M
73.73 M
Profit Margin
N/A
N/A
-1.14
-3.0
-1.42
N/A
N/A
N/A
N/A
-0.82
EBITDA
(89.62 M)
(102.38 M)
(22.76 M)
(146.76 M)
(145.92 M)
(430.58 M)
(86.02 M)
(76.42 M)
(98.34 M)
(35.45 M)
Current Valuation
(73.69 M)
30.57 M
(5.33 M)
37.86 M
96.24 M
8.09 B
47.82 M
(17.08 M)
(25.9 M)
475.25 M
Price To Book
0.22
2.39
1.29
2.58
218.61
6.1
1.41
0.28
0.46
108.42
Operating Margin
N/A
-74.06
-0.57
-1.93
-1.33
-845.95
N/A
N/A
N/A
-2.73
Retained Earnings
(501.34 M)
(536.13 M)
(314.96 M)
(1.34 B)
(1.96 B)
(1.14 B)
(417.43 M)
(456.92 M)
(594.47 M)
(352.52 M)
Current Asset
N/A
78.33 M
31.66 M
1.11 B
63.4 M
N/A
123.51 M
60.02 M
144.91 M
119.62 M
Beta
1.93
2.1
0.66
1.6
1.39
1.4
2.52
1.17
1.2
2.1
Number Of Employees
58
76
46
273
389
490
54
90
58
53
Shares Outstanding
39.26 M
16.39 M
1.32 M
96.69 M
23.46 M
168.22 M
56.59 M
38.41 M
61.77 M
21.4 M
Cash Flow From Operations
(101.46 M)
(110.27 M)
(53.82 M)
(118.69 M)
(224.2 M)
(350.57 M)
(66.72 M)
(65.08 M)
(78.26 M)
(69.38 M)
Total Debt
58.23 M
19.35 M
11.92 M
124.38 M
350.25 M
87.94 M
25.3 M
63.88 M
26.29 M
16.01 M
Return On Equity
-0.91
-1.24
-0.8
-7.06
-12.79
-0.47
-0.63
-1.83
-0.64
-2.84
Z Score
-3.54
N/A
N/A
N/A
N/A
N/A
N/A
-5.25
N/A
10.72
Return On Asset
-0.35
-0.49
-0.13
-0.21
-0.22
-0.29
-0.33
-0.51
-0.34
-0.36
Number Of Shares Shorted
360.89 K
982.93 K
22.5 K
3.17 M
2.8 M
18.14 M
6.33 M
272.73 K
1.64 M
1.16 M
Book Value Per Share
2.58
3.85
21.64
-1.78
-13.48
9.34
1.72
0.27
2.03
1.11
Current Liabilities
N/A
8.94 M
2.8 M
288.7 M
9.97 M
N/A
4.43 M
3.56 M
3.09 M
18.4 M
Total Asset
208.24 M
97.16 M
38.68 M
354.78 M
313.91 M
2.06 B
158.57 M
155.03 M
150.54 M
73.73 M
Debt To Equity
0.29
0.097
0.3
2.76
5.88
0.13
0.19
0.57
0.11
0.43
Short Ratio
1.29
12.46
3.52
9.62
9.01
14.94
7.7
0.16
6.61
0.37
Target Price
6.43
26.74
7.0
8.4
8.0
71.43
14.5
5.5
7.67
23.67
Shares Owned By Institutions
54.32
36.98
52.92
61.39
37.14
97.87
98.99
24.54
59.68
82.85
Market Capitalization
58.11 M
43.28 M
21.14 M
187.58 M
67.09 M
9.55 B
137.5 M
3.02 M
33.11 M
492.35 M
Price To Earning
N/A
-2.04
-6.95
19.8
10.52
N/A
N/A
-3.53
N/A
-5.61
Price To Earnings To Growth
N/A
N/A
N/A
0.74
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
N/A
5.83
1.01
2.65
0.42
12872.61
N/A
N/A
N/A
13.19
Net Income
(151.82 M)
(105.94 M)
(24.54 M)
(240.05 M)
(245.76 M)
(436.37 M)
(82.44 M)
(97.76 M)
(102.06 M)
(30.5 M)
Earnings Per Share
-4.2
-4.8
-12.11
-2.39
-11.02
-3.66
-1.33
-2.5
-1.17
-8.62
Shares Owned By Insiders
1.5
6.0
0.06
21.02
1.22
2.13
2.26
2.73
0.49
0.34
Revenue
N/A
8.28 M
42.81 M
69.56 M
156.31 M
11.58 M
N/A
N/A
N/A
37.34 M
Working Capital
113.56 M
58.28 M
36.84 M
268.62 M
(143.48 M)
1.74 B
114.39 M
61.73 M
101.62 M
2.29 M
Cash And Equivalents
175.99 M
237.23 M
80.94 M
376.78 M
218.23 M
461.43 M
160.89 M
101.73 M
239.25 M
90.15 M
Cash Per Share
4.55
1.59
1.09
4.9
0.72
5.26
4.43
2.64
4.39
2.72
Gross Profit
N/A
42.87 M
(27.08 M)
35.1 M
82.61 M
(217.69 M)
N/A
N/A
N/A
(49.48 M)
Day Typical Price
1.48
2.75
15.78
1.97
2.78
57.47
2.46
1.06
0.53
0.84
Accumulation Distribution
N/A
0.11
0.0387
0.049
0.0938
0.0396
0.0703
0.0804
0.0727
0.0465
Market Facilitation Index
N/A
0.32
0.62
0.1
0.27
2.33
0.18
0.09
0.04
0.04
Daily Balance Of Power
0.0
(0.25)
(0.13)
(0.40)
0.7037
0.1288
(0.67)
(0.22)
0.75
N/A
Period Momentum Indicator
N/A
(0.08)
(0.08)
(0.04)
0.19
0.3
(0.12)
(0.02)
0.03
N/A
Rate Of Daily Change
1.0
0.97
1.0
0.98
1.07
1.01
0.95
0.98
1.06
1.0
Day Median Price
1.48
2.8
15.7
1.99
2.75
57.67
2.47
1.08
0.53
0.84
Price Action Indicator
N/A
(0.20)
0.19
(0.07)
0.21
(0.44)
(0.10)
(0.04)
0.025
0.01
Coefficient Of Variation
1404.52
(564.51)
(1,239)
(864.75)
(605.56)
690.11
(405.97)
2475.92
(1,748)
846.77
Mean Deviation
3.16
2.49
1.56
3.52
3.56
2.06
3.84
3.9
4.66
3.55
Jensen Alpha
0.4374
(0.79)
(0.23)
(0.79)
(1.06)
0.2459
(1.19)
0.2345
(0.57)
0.4301
Total Risk Alpha
(0.33)
(1.15)
(0.47)
(1.13)
(1.41)
0.0277
(1.82)
(0.47)
(1.09)
(0.07)
Sortino Ratio
0.0708
N/A
N/A
N/A
N/A
0.1038
N/A
0.017
N/A
0.1143
Downside Variance
15.4
N/A
N/A
N/A
N/A
6.62
N/A
33.68
N/A
15.83
Standard Deviation
5.44
3.7
2.16
4.55
4.74
2.6
4.8
5.15
5.78
4.78
Kurtosis
21.78
1.99
2.26
0.2448
3.16
(0.10)
0.4996
0.6864
(0.50)
1.18
Potential Upside
5.77
6.39
2.69
6.98
6.43
4.81
5.81
7.53
9.33
9.59
Treynor Ratio
(0.62)
(0.51)
(0.41)
(0.21)
(0.29)
0.3019
19.48
(0.54)
(0.15)
0.4444
Maximum Drawdown
43.6
21.26
12.92
22.87
27.05
10.95
26.0
23.8
25.5
22.48
Variance
29.56
13.68
4.68
20.68
22.48
6.76
23.04
26.57
33.35
22.82
Market Risk Adjusted Performance
(0.61)
(0.50)
(0.40)
(0.20)
(0.28)
0.3119
19.49
(0.53)
(0.14)
0.4544
Risk Adjusted Performance
0.0629
(0.13)
(0.06)
(0.08)
(0.12)
0.1176
(0.18)
0.0393
(0.03)
0.0985
Skewness
3.52
0.4688
0.6346
0.2039
(1.04)
(0.03)
0.304
(0.55)
(0.14)
0.8356
Semi Deviation
3.26
N/A
N/A
N/A
N/A
2.2
N/A
5.0
N/A
3.28
Information Ratio
0.0511
(0.21)
(0.13)
(0.14)
(0.19)
0.1028
(0.27)
0.0192
(0.08)
0.0952
Value At Risk
(6.25)
(6.82)
(3.40)
(7.81)
(8.60)
(3.90)
(8.30)
(9.65)
(9.88)
(6.25)
Expected Short fall
(4.40)
N/A
N/A
N/A
N/A
(2.13)
N/A
(4.64)
N/A
(5.07)
Downside Deviation
3.92
N/A
N/A
N/A
N/A
2.57
N/A
5.8
N/A
3.98
Semi Variance
10.66
N/A
N/A
N/A
N/A
4.84
N/A
25.05
N/A
10.79

Tcr2 Therapeutics Competition Performance Charts

Five steps to successful analysis of Tcr2 Therapeutics Competition

Tcr2 Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Tcr2 Therapeutics in relation to its competition. Tcr2 Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Tcr2 Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Tcr2 Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Tcr2 Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Tcr2 Therapeutics position

In addition to having Tcr2 Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Developed Markets Basket ETFs Thematic Idea Now

Developed Markets Basket ETFs
Developed Markets Basket ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Developed Markets Basket ETFs theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Developed Markets Basket ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Other Consideration for investing in Tcr2 Stock

If you are still planning to invest in Tcr2 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tcr2 Therapeutics' history and understand the potential risks before investing.
Global Correlations
Find global opportunities by holding instruments from different markets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY